| Literature DB >> 29526553 |
Maxime W C Rousseaux1, Tyler Tschumperlin2, Hsiang-Chih Lu3, Elizabeth P Lackey4, Vitaliy V Bondar1, Ying-Wooi Wan1, Qiumin Tan1, Carolyn J Adamski1, Jillian Friedrich2, Kirk Twaroski5, Weili Chen5, Jakub Tolar5, Christine Henzler6, Ajay Sharma1, Aleksandar Bajić1, Tao Lin7, Lisa Duvick2, Zhandong Liu8, Roy V Sillitoe4, Huda Y Zoghbi9, Harry T Orr10.
Abstract
Polyglutamine (polyQ) diseases are caused by expansion of translated CAG repeats in distinct genes leading to altered protein function. In spinocerebellar ataxia type 1 (SCA1), a gain of function of polyQ-expanded ataxin-1 (ATXN1) contributes to cerebellar pathology. The extent to which cerebellar toxicity depends on its cognate partner capicua (CIC), versus other interactors, remains unclear. It is also not established whether loss of the ATXN1-CIC complex in the cerebellum contributes to disease pathogenesis. In this study, we exclusively disrupt the ATXN1-CIC interaction in vivo and show that it is at the crux of cerebellar toxicity in SCA1. Importantly, loss of CIC in the cerebellum does not cause ataxia or Purkinje cell degeneration. Expression profiling of these gain- and loss-of-function models, coupled with data from iPSC-derived neurons from SCA1 patients, supports a mechanism in which gain of function of the ATXN1-CIC complex is the major driver of toxicity.Entities:
Keywords: ATXN1; CIC; RAN translation; RNA toxicity; ataxia; cerebellum; neurodegeneration; polyglutamine; toxicity
Mesh:
Substances:
Year: 2018 PMID: 29526553 PMCID: PMC6422678 DOI: 10.1016/j.neuron.2018.02.013
Source DB: PubMed Journal: Neuron ISSN: 0896-6273 Impact factor: 17.173